Veracyte, Inc. (VCYT) Stock Price & How to Invest

Veracyte is a US genomic diagnostics company that develops and runs advanced molecular tests used to guide cancer treatment decisions. Its two flagship products drive the business: Decipher, a genomic classifier for prostate cancer, and Afirma, which helps assess indeterminate thyroid nodules to avoid unnecessary surgeries. The company also markets tests in other areas and runs a research platform (Afirma GRID, Decipher studies) built on large proprietary genomic sample databases that act as a competitive moat. Testing revenue is the dominant and fastest-growing part of the mix.

The investment picture is one of a diagnostics company that has crossed into sustained profitability, a relative rarity in the space. Q1 2026 revenue rose roughly 21% year over year to about $139M with GAAP net income of about $29M and an adjusted EBITDA margin near 31%, and management raised full-year guidance. The tradeoff is valuation: the stock carries a P/E in the mid-40s and a market cap around $4.6B, so much of the near-term growth is already priced in, and the concentration in two tests plus reimbursement dependence are the key things to weigh.

Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The stock trades at a premium valuation (P/E in the mid-40s), which amplifies downside if growth decelerates or guidance is missed. Medicare and commercial payer decisions drive a large portion of realized revenue, making pricing and coverage a persistent uncertainty. Larger diagnostics rivals such as Exact Sciences, Guardant Health, and Natera have deeper resources and are expanding into overlapping oncology testing areas. New-test launches and international expansion carry execution and regulatory risk.

11 analysts publish price targets on VCYT, averaging $57.82 against a $43.43 price as of September 2026, or +33.1%. The published targets run from $44.00 to $70.00, a moderate spread, and the ratings split 10 buy, 1 hold, 1 sell. Over the last six months there have been 5 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VCYT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Veracyte, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Decipher prostate franchise. Decipher is the largest and fastest-growing revenue line, up roughly 30% year over year in Q1 2026 to about $87M in testing revenue. The most optimistic published target, $70.00, assumes this works close to its best case.

The case against. Revenue is heavily concentrated in just two tests, so any reimbursement change, coverage denial, or competitive share loss in prostate or thyroid diagnostics would hit results disproportionately. The most pessimistic target, $44.00, is roughly what VCYT is worth if this bites instead.

Read the full bull and bear case on VCYT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Veracyte, Inc. (VCYT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Veracyte, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$517M
• Q1 2026 revenue: ~$139M (up ~21% YoY)
• Net income (TTM): ~$66M
• 2026 revenue guidance: ~$582M to $592M
• Market cap: ~$4.6B
• P/E (trailing): ~45x

Veracyte is profitable on a GAAP basis with an adjusted EBITDA margin near 31% in Q1 2026, an uncommon profile among growth-stage diagnostics firms. The mid-40s P/E sits well above the broader biotech average, reflecting the market pricing in continued double-digit testing growth. Figures are approximate and drawn from the most recent reported quarter and guidance.

Other names that sit close to VCYT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VCYT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VCYT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VCYT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

VCYT is a rare profitable, cash-generative diagnostics name, but its rich multiple leaves little room for a growth stumble in its two core tests.

Whether VCYT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VCYT a buy or a sell?, and where the stock could go from here in the VCYT stock forecast.

For income investors, whether VCYT pays a dividend and how the payout looks is covered in does VCYT pay a dividend? And to weigh VCYT against a peer, read the full side-by-side comparisons: VCYT vs GH and VCYT vs GRAL.